New trends in pharmacogenomic strategies against resistance development in microbial infections

Pharmacogenomics

Volumn 9, Issue 11, 2008, Pages 1711-1723

  Ohlsen, Knut ^a   Dandekar, Gudrun ^a   Schwarz, Roland ^a   Dandekar, Thomas ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

Author keywords

bioinformatics; innate immunity; lipopeptides; modeling; pharmacogenomics; resistance; target identification

Indexed keywords

AMINOPENICILLIN; APTAMER; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CLOPENTHIXOL; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DEPSIPEPTIDE; DORIPENEM; ICLAPRIM; KETOLIDE; LINEZOLID; MACROLIDE; METICILLIN; ORITAVANCIN; OXACILLIN; POLYMYXIN DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; SILVER; TELAVANCIN; TETRACYCLINE; THIORIDAZINE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BIOINFORMATICS; COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; DRUG TARGETING; ENTEROBACTERIACEAE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; HUMAN; INFECTION; INTEGRON; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PERSONAL HYGIENE; PHARMACOGENOMICS; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TRANSPOSON; ANIMAL; DRUG EFFECT; GENETICS; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; METHODOLOGY; MICROBIOLOGY; PHARMACOGENETICS;

HELICOBACTER PYLORI; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; PHARMACOGENETICS;

EID: 61549113146     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.11.1711     Document Type: Review

References (59)

1. ONeill AJ: New antibacterial agents for treating infections caused by multi-drug resistant Gram negative bacteria. Expert Opin. Investig. Drugs 17(3), 297-302 (2008).
2. Ziebuhr W, Xiao K, Coulibaly B, Schwarz R, Dandekar T: Pharmacogenomic strategies against resistance development in microbial infections. Pharmacogenomics 5(4), 361-379, (2004). (Pubitemid 38923651)
3. Martins A, de Lourdes RS, Cunha M: Methicillin resistance in Staphylococcus aureus and coagulase-negative staphylococci: epidemiological and molecular aspects. Microbiol. Immunol. 51(9), 787-795 (2007). (Pubitemid 47450475)
4. Appelbaum PC: MRSA -the tip of the iceberg. Clin. Microbiol. Infect. 12(Suppl. 2), 3-10 (2006).
5. Micek ST: Alternatives to vancomycin for the treatment of methicillinresistant Staphylococcus aureus infections. Clin. Infect. Dis. 45(Suppl. 3), S184-S190 (2007). (Pubitemid 47378905)
6. Pantosti A, Sanchini A, Monaco M: Mechanisms of antibiotic resistance in Staphylococcus aureus. Future Microbiol. 2, 323-334 (2007). (Pubitemid 47180928)
7. Goldstein F: The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J. Antimicrob. Chemother. 59(1), 1-4 (2007). (Pubitemid 46017894)
8. Klare I, Konstabel C, Mueller-Bertling S, et al. Spread of ampicillin/vancomycinresistant Enterococcus faecium of the epidemic-virulent clonal complex-17 carrying the genes esp and hyl in German hospitals. Eur. J. Clin. Microbiol. Infect. Dis. 24, 815-825 (2005). (Pubitemid 43042788)
9. Leavis HL, Bonten MJM, Willems RJL: Identification of high-risk enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr. Opin. Microbiol. 9, 454-460 (2006).
10. Witte W, Cuny C, Klare I, et al. Emergence and spread of antibiotic-resistant Gram positive bacterial pathogens. Int. J. Med. Microbiol. 298(5-6), 365-377 (2008).
11. Aspa J, Rajas O, de Castro FR: Pneumococcal antimicrobial resistance: therapeutic strategy and management in community acquired pneumonia. Expert Opin. Pharmacother. 9(2), 229-241 (2008). (Pubitemid 351233731)
12. Catalanotti P, Catania MR, Lucido M, et al. T serotyping and genomic profile of erythromycin-resistant or -sensitive Streptococcus pyogenes isolated in Campania Region, Italy. J. Chemother. 17(2), 131-137 (2005). (Pubitemid 40732872)
13. Dijkshoorn L, Nemec A, Seifert H: An increasing threat in hospitals: multidrugresistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5(12), 939-951 (2007). (Pubitemid 350131182)
14. Rice LB: Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl. 2), S100-S105 (2006).
15. Nordmann P, Naas T, Fortineau N, Poirel L: Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr. Opin. Microbiol. 10(5), 436-440 (2007). (Pubitemid 350064580)
16. Jacoby GA, Munoz-Price LS: The new b-lactamases. N. Engl. J. Med. 352(4), 380-391 (2005).
17. Zambon C-F, Fasolo M, Basso D, et al. Clarithromycin resistance, tumor necrosis factor a gene polymorphism and mucosal inflammation affect H. pylori eradication success. J. Gastrointest. Surg. 11(11), 1506-1514 (2007).
18. Hotomi M, Fujihara K, Billal DS, et al. Genetic characteristics and clonal dissemination of b-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. Antimicrob. Agents Chemother. 51(11), 3969-3976 (2007). (Pubitemid 350057795)
19. Tristram S, Jacobs MR, Appelbaum PC: Antimicrobial resistance in Haemophilus influenzae. Clin. Microbiol. Rev. 20(2), 368-389 (2007). (Pubitemid 46709308)
20. Levin BR, Rozen DE: Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4(7), 556-562 (2006).
21. Rachman H, Kaufmann SHE: Exploring functional genomics for the development of novel intervention strategies against TB. Int. J. Med. Microbiol. 297(7-8), 559-567 (2007). (Pubitemid 47575959)
22. Wagner A: Cooperation is fleeting in the world of transposable elements. PLoS Comput. Biol. 2(12), E162 (2006). (Pubitemid 46045165)
23. Mazel D: Integrons: agents of bacterial evolution. Nat. Rev. Microbiol. 4(8), 608-620 (2006). (Pubitemid 44317023)
24. Coates ARM, Hu Y: Novel approaches to developing new antibiotics for bacterial infections. Br. J. Pharmacol. 152(8), 1147-1154 (2007). (Pubitemid 350242433)
25. Peschel A, Sahl H-G: The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4(7), 529-536 (2006). (Pubitemid 43905612)
26. Brtz-Oesterhelt H, Beyer D, Kroll H-P, et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat. Med. 11(10), 1082-1087 (2005). (Pubitemid 41486830)
27. Schneiker S, Perlova O, Kaiser O, et al. Complete genome sequence of the myxobacterium Sorangium cellulosum. Nat. Biotechnol. 25(11), 1281-1289 (2007). (Pubitemid 350076516)
28. Feil H, Feil WS, Chain P, et al. Comparison of the complete genome sequences of Pseudomonas syringae pv. syringae B728a and pv. tomato DC3000. Proc. Natl. Acad. Sci. USA 102(31), 11064-11069 (2005). (Pubitemid 41105993)
29. Raes J, Korbel JO, Lercher MJ, von Mering C, Bork P: Prediction of effective genome size in metagenomic samples. Genome Biol. 8(1), R10 (2007). (Pubitemid 351910992)
30. Singer RS, Ward MP, Maldonado G: Can landscape ecology untangle the complexity of antibiotic resistance? Nat. Rev. Microbiol. 4(12), 943-952 (2006). (Pubitemid 44768256)
31. Chopra I: The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern? J. Antimicrob. Chemother. 59(4), 587-590 (2007). (Pubitemid 47073388)
32. Livermore DM: Introduction: the challenge of multiresistance. Int. J. Antimicrob. Agents (Suppl. 3) S1-S7 (2007).
33. Vergidis PI, Falagas ME: Multidrug-resistant Gram negative bacterial infections: the emerging threat and potential novel treatment options. Curr. Opin. Investig. Drugs 9(2), 176-183 (2008).
34. Sugimoto M, Furuta T, Shirai N, et al. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin. Pharmacother. 8(16), 2701-2717 (2007). (Pubitemid 350193712)
35. Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A: Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol. Rev. 30(5), 673-691 (2006). (Pubitemid 44199345)
36. Lock RL, Harry EJ: Cell-division inhibitors: new insights for future antibiotics. Nat. Rev. Drug Discov. 7(4), 324-338 (2008).
37. Poehlsgaard J, Douthwaite S: The bacterial ribosome as a target for antibiotics. Nat. Rev. Microbiol. 3(11), 870-881 (2005). (Pubitemid 41693182)
38. Raddatz M-SL, Dolf A, Endl E, et al. Enrichment of cell-targeting and populationspecific aptamers by fluorescence-activated cell sorting. Angew. Chem. Int. Ed. Engl. 47(28), 5190-5193 (2008).
39. Lee JF, Stovall GM, Ellington AD: Aptamer therapeutics advance. Curr. Opin. Chem. Biol. 10(3), 282-289 (2006).
40. Kristiansen JE, Hendricks O, Delvin T, et al. Reversal of resistance in microorganisms by help of non-antibiotics. J. Antimicrob. Chemother. 59(6), 1271-1279 (2007). (Pubitemid 47073346)
41. Poole K: Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 39(3), 162-176 (2007). (Pubitemid 46676478)
42. Brown EM, Nathwani D: Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J. Antimicrob. Chemother. 55(1), 6-9 (2005). (Pubitemid 40192608)
43. Kollef MH: Is antibiotic cycling the answer to preventing the emergence of bacterial resistance in the intensive care unit? Clin. Infect. Dis. 43(Suppl. 2), S82-S88 (2006).
44. Foucault C, Brouqui P: How to fight antimicrobial resistance. FEMS Immunol. Med. Microbiol. 49(2), 173-183 (2007). (Pubitemid 46257123)
45. Engelmann S, Hecker M: Proteomic analysis to investigate regulatory networks in Staphylococcus aureus. Methods Mol. Biol. 431, 25-45 (2008). (Pubitemid 351366048)
46. Becker D, Selbach M, Rollenhagen C, et al. Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature 440(7082), 303-307 (2006).
47. Dittrich M, Birschmann I, Mietner S, et al. Platelet protein interactions. Map, signaling components, and phosphorylation groundstate. Arterioscler. Thromb. Vasc. Biol. 28(7), 1326-1331 (2008).
48. Park H, Kwon Y, Ki C-S, et al. Interleukin-12 Receptor b1 polymorphisms and nontuberculous mycobacterial lung diseases. Lung 186(4), 241-245 (2008).
49. Gumbo T: Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy. Curr. Opin. Drug Discov. Devel. 11(1), 32-42 (2008).
50. Nomura S, Kondo M, Nagano M, Matsui K, Egashira T: Development of a novel nano-Invader DNA chip system. J. Biochem. Biophys. Methods 70(5), 787-795 (2007). (Pubitemid 47021224)
51. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat. Med. 13(4), 463-469 (2007).
52. Overhage J, Campisano A, Bains M, et al. Human host defence peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76(9), 4176-4182 (2008).
53. Ohlsen K, Lorenz U: Novel targets for antibiotics in Staphylococcus aureus. Future Microbiol. 2, 655-666 (2007).
54. Projan SJ, Nesin M, Dunman PM: Staphylococcal vaccines and immunotherapy: to dream the impossible dream? Curr. Opin. Pharmacol. 6(5), 473-479 (2006). (Pubitemid 44362069)
55. Muzzi A, Masignani V, Rappuoli R: The pan-genome: towards a knowledge-based discovery of novel targets for vaccines and antibacterials. Drug Discov. Today 12(11-12), 429-439 (2007). (Pubitemid 46783689)
56. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. USA 103(29), 10834-10839 (2006). (Pubitemid 44148381)
57. Miller E, Pollard A, Borrow R: Safety and immunogenicity of Novartis Meningococcal serogroup B vaccine after three doses administered in infancy. European Society for Paediatric Infectious Diseases (ESPID) Annual Meeting. Graz, Austria, May 13-17 (2008).
58. Mora M, Donati C, Medini D, Covacci A, Rappuoli R: Microbial genomes and vaccine design: refinements to the classical reverse vaccinology approach. Curr. Opin. Microbiol. 9(5), 532-536 (2006). (Pubitemid 44397631)
59. Amino Acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant b-lactamases. www.lahey.org/Studies/